Business
Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities
Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities\n\n\n\n\n\nCannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities\nDr. Zohar will support strategic business planning as Cannabics enters $10 million Standby Equity Distribution Agreement with YAII PN, Ltd.\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, May 2, 2018\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, May 2, 2018 /PRNewswire/ --\n\nCannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, today announced that CEO of Life Source Partners Ltd., Muriel Zohar, Ph.D, MBA, will be working with Cannabics to advance personalized and palliative cannabinoid cancer care. Dr. Zohar brings a diversified background in private equity and therapeutic drug development to her new role.\n\n     (Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )\n\n\n\"Cannabics has demonstrated strong expertise in cannabinoid data and technology applications to enable a future of more effective and targeted care,\" said Dr. Zohar. \"I look forward to supporting the Cannabics team by assessing new project opportunities and providing strategic business insight to help maintain the company's leadership in cannabinoid diagnostics and therapeutic applications within the rapidly expanding industry.\"\n\nDr. Zohar has led business development and research activities for several healthcare technology, finance and biopharmaceutical companies including Ofer Hi-Tech and Bio-Technology General (BTG). Her numerous global clients include both large and small pharmaceutical companies along with private equity and development funds. She holds a doctoral degree from the Weizmann Institute of Science and completed her postdoctoral training in Molecular Oncology at the National Institute of Health as a distinguished Intramural Research Training Award fellow. Dr. Zohar also holds an MBA degree from Bar Ilan University in Israel.\n\nIn addition to assessing project opportunities, Dr. Zohar will support the management of a new Cannabics equity line. The company has secured a $10 million Standby Equity Distribu...